These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 1352243)

  • 21. Prolactinomas in pregnancy: considerations before conception and during pregnancy.
    Glezer A; Bronstein MD
    Pituitary; 2020 Feb; 23(1):65-69. PubMed ID: 31792668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of Prolactinoma.
    Inder WJ; Jang C
    Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hyperprolactinaemia.
    Prabhakar VK; Davis JR
    Best Pract Res Clin Obstet Gynaecol; 2008 Apr; 22(2):341-53. PubMed ID: 17889620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
    Dogansen SC; Selcukbiricik OS; Tanrikulu S; Yarman S
    Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine.
    van der Lely AJ; Brownell J; Lamberts SW
    J Clin Endocrinol Metab; 1991 May; 72(5):1136-41. PubMed ID: 1673685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
    Hamilton DK; Vance ML; Boulos PT; Laws ER
    Pituitary; 2005; 8(1):53-60. PubMed ID: 16411069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms.
    Pivonello C; Patalano R; Negri M; Pirchio R; Colao A; Pivonello R; Auriemma RS
    Front Endocrinol (Lausanne); 2021; 12():791633. PubMed ID: 35095761
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of dopamine agonists on prolactinomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI).
    Manuchehri AM; Sathyapalan T; Lowry M; Turnbull LW; Rowland-Hill C; Atkin SL
    Pituitary; 2007; 10(3):261-6. PubMed ID: 17557207
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hyperprolactinemia and prolactinoma.
    Romijn JA
    Handb Clin Neurol; 2014; 124():185-95. PubMed ID: 25248588
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Update on prolactinomas. Part 2: Treatment and management strategies.
    Wong A; Eloy JA; Couldwell WT; Liu JK
    J Clin Neurosci; 2015 Oct; 22(10):1568-74. PubMed ID: 26243714
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New medical approaches in pituitary adenomas.
    Colao A; Di Sarno A; Marzullo P; Di Somma C; Cerbone G; Landi ML; Faggiano A; Merola B; Lombardi G
    Horm Res; 2000; 53 Suppl 3():76-87. PubMed ID: 10971110
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The best approach to treat prolactinoma].
    Zárate A; Saucedo R; Basurto L
    Gac Med Mex; 2004; 140(5):567-9. PubMed ID: 15559242
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short-term preoperative treatment of macroprolactinomas by dopamine agonists.
    Fahlbusch R; Buchfelder M; Schrell U
    J Neurosurg; 1987 Dec; 67(6):807-15. PubMed ID: 3681420
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Macroprolactinomas and Nonfunctioning Pituitary Adenomas and Pregnancy Outcomes.
    Lambert K; Rees K; Seed PT; Dhanjal MK; Knight M; McCance DR; Williamson C
    Obstet Gynecol; 2017 Jan; 129(1):185-194. PubMed ID: 27926659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.
    Di Sarno A; Landi ML; Cappabianca P; Di Salle F; Rossi FW; Pivonello R; Di Somma C; Faggiano A; Lombardi G; Colao A
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5256-61. PubMed ID: 11701688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Macroprolactinomas and functionless pituitary tumours. Immunostaining and effect of dopamine agonist therapy.
    Gasser RW; Mueller-Holzner E; Skrabal F; Finkenstedt G; Mayr U; Tabarelli M; Spoendlin H; Grunert V; Twerdy K
    Acta Endocrinol (Copenh); 1987 Oct; 116(2):253-9. PubMed ID: 3116800
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Shrinkage of a PRL-secreting pituitary macroadenoma resistant to cabergoline.
    Cannavò S; Bartolone L; Blandino A; Spinella S; Galatioto S; Trimarchi F
    J Endocrinol Invest; 1999 Apr; 22(4):306-9. PubMed ID: 10342366
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas.
    Luque GM; Perez-Millán MI; Ornstein AM; Cristina C; Becu-Villalobos D
    J Pharmacol Exp Ther; 2011 Jun; 337(3):766-74. PubMed ID: 21406548
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.
    Cristina C; Díaz-Torga GS; Goya RG; Kakar SS; Perez-Millán MI; Passos VQ; Giannella-Neto D; Bronstein MD; Becu-Villalobos D
    Mol Cancer; 2007 Jan; 6():4. PubMed ID: 17222350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CV 205-502 treatment of macroprolactinomas.
    Crottaz B; Uske A; Reymond MJ; Rey F; Siegel RA; Brownell J; Gomez F
    J Endocrinol Invest; 1991 Oct; 14(9):757-62. PubMed ID: 1684803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.